# Dexanabinol in Severe Traumatic Brain Injury

> **NCT00129857** · PHASE3 · COMPLETED · sponsor: **Pharmos** · enrollment: 860 (—)

## Conditions studied

- Traumatic Brain Injury

## Interventions

- **DRUG:** Dexanabinol

## Key facts

- **NCT ID:** NCT00129857
- **Lead sponsor:** Pharmos
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** —
- **Final completion:** 2004-09
- **Target enrollment:** 860 (—)
- **Last updated:** 2006-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129857, "Dexanabinol in Severe Traumatic Brain Injury". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00129857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*